Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380051 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL29892 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL35541 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL1452757 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL3457992 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL29341 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL15229292 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL2903635 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL19579380 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL6465406 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717744-A1 | USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE | Bostik SA (FR) | 2026-04-01 | — | — | EP | claimed |
| EP-3852815-B1 | STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF | CHEMENCE MEDICAL INC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20250215132-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2025-07-03 | — | — | US | claimed |
| CN-119455136-A | Biodegradable stent, preparation method thereof and biodegradable stent system | 上海畅德医疗科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119451941-A | Bio-based cyanoacrylate compounds | 博斯蒂克股份公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4504844-A1 | TWO-PART CURABLE COMPOSITION | Bostik SA (FR) | 2025-02-12 | — | — | EP | claimed |
| US-20240240064-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2024-07-18 | — | — | US | claimed |
| EP-4334368-A1 | TWO-PART CURABLE COMPOSITION | Bostik SA (FR) | 2024-03-13 | — | — | EP | claimed |
| CN-117377706-A | Two-part curable composition | 博斯蒂克股份公司 | 2024-01-09 | — | — | CN | claimed |
| EP-4274628-A1 | CATHETER SECUREMENT COMPOSITIONS AND METHODS | Adhezion Biomedical, LLC (US) | 2023-11-15 | — | — | EP | claimed |
| US-20220218951-A1 | CATHETER SECUREMENT COMPOSITIONS AND METHODS PROVIDING SIGNIFICANTLY STRONG SECUREMENT, WATER RESISTANT SEAL, EFFECTIVE HEMOSTATIS, AND ANTIBACTERIAL PROPERTIES AT AND AROUND VASCULAR ACCESS SITES | H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. | 2022-07-14 | — | — | US | claimed |
| CN-114732941-A | Preparation method of cleaning and antibacterial gel | 安徽徽科生物工程技术有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-108203482-B | Negative electrode binder and preparation method thereof and preparation method of negative electrode piece | 珠海冠宇电池股份有限公司 | 2020-09-15 | — | — | CN | claimed |
| CN-111480923-A | Degradable nitrile rubber glove forming preparation method | 安徽攀望科技有限公司 | 2020-08-04 | — | — | CN | claimed |
| US-20160190591-A1 | LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | DONGGUAN AMPEREX TECHNOLOGY LIMITED (CN) | 2016-06-30 | — | — | US | claimed |
| WO-2013129722-A1 | TISSUE ADHESIVE FOR WOUND CLOSURE AND PREPARATION METHOD THEREOF | GENEWEL CO., LTD (KR) | 2013-09-06 | — | — | WO | claimed |
| EP-2219553-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | Valor Medical, Inc. (US) | 2010-08-25 | — | — | EP | claimed |
| US-20100112036-A1 | Cyanoacrylate-based liquid microbial sealant drape | ADHEZION BIOMEDICAL, LLC. (US) | 2010-05-06 | — | — | US | claimed |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-10-15 | — | — | US | claimed |
| WO-2009064698-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | HCAR2 781/4885ATM 652/4885NAAA 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.